Sorin Group Announces the First Implant of Solo Smart in the United States

Sorin Group, (Reuters Code: SORN.MI) (MIL:SRN), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today that the first US implant of Solo Smart was performed by David Heimansohn, M.D. at St. Vincent’s Heart Hospital, Indianapolis (IN).

Solo Smart is the first and only valve with a removable stent to be approved in the US market. This unique bioprosthesis, made from bovine pericardium, has no synthetic material added, allowing it to mimic the healthy native aortic valve. Solo Smart maximizes blood flow and delivers excellent hemodynamic performance, while providing the ease of implantability of a stented valve.

"I am excited to have the Sorin Solo Smart stentless valve available to my patients," said David Heimansohn, M.D., St. Vincent Heart Center, Indianapolis, Indiana. "Solo Smart is a step forward in the treatment of aortic valve disease, as this surgical valve has superior hemodynamic performance, and is much easier to implant, requiring only a single suture line. It more resembles a native aortic valve in appearance and performance, offering the best hemodynamics during all conditions, and improving patients' lives dramatically”, added Dr. Heimansohn.

Solo Smart is the next generation of the Freedom Solo valve which has been available in Europe since 2004.

"The first US implant of Solo Smart is a huge milestone for Sorin,” said Michel Darnaud, President, Cardiac Surgery Business Unit, Sorin Group. "Solo Smart is the evidence of Sorin’s continuous commitment to providing new and innovative solutions to improve patients’ lives”.

About Sorin Group

Sorin Group (www.sorin.com) is a global, medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With over 3,500 employees worldwide,Sorin Group focuses on two major therapeutic areas: Cardiac Surgery (cardiopulmonary products for open heart surgery and heart valve repair or replacement prostheses) and Cardiac Rhythm Management (pacemakers, defibrillators and non invasive monitoring to diagnose arrhythmias and deliver anti-arrhythmia therapies as well as cardiac resynchronization devices for heart failure treatment) Every year, over one million patients are treated with Sorin Group devices in more than 100 countries.

www.sorin.com

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20141007005377/en/